While initial genetic manipulation has confirmed that inhibiting KLF5 can reduce the stemness of ovarian cancer cells and increase their sensitivity to PARPi, this study further explored the clinical application prospects of this mechanism using the KLF5 inhibitor ML264 for in vitro and in vivo validation. Here, KLF5 is linked to ovarian cancer.